New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ADTN;EXPR;GGC;MDRX;QCOR From The Last 14 Days
Check below for free stories on ADTN;EXPR;GGC;MDRX;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
07:51 EDTMDRXAllscripts has reached attractive entry point, says RBC Capital
Subscribe for More Information
August 15, 2014
10:20 EDTMDRXAllscripts management to meet with Maxim
Subscribe for More Information
06:08 EDTQCORQuestcor implied volatility of 28 at lower end of index mean range
Subscribe for More Information
August 14, 2014
17:21 EDTQCORGulfMark Offshore to replace Questcor in S&P 600 as of 8/18 close
17:16 EDTQCORPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:35 EDTQCORMallinckrodt completes acquisition of Questcor Pharmaceuticals
Subscribe for More Information
13:02 EDTQCORMallinckrodt, Questcor holders approve Mallinckrodt's acquisition of Questcor
Subscribe for More Information
07:33 EDTMDRXAllscripts sell-off creates attractive entry point, says Jefferies
Subscribe for More Information
06:35 EDTMDRXAllscripts volatility flat on wide price movement
Allscripts September call option implied volatility is at 32, December is at 33; compared to its 26-week average of 32 according to Track Data, suggesting non-directional price movement.
August 13, 2014
16:11 EDTMDRXAllscripts expands partnership with Clinical Architecture
Subscribe for More Information
August 8, 2014
09:15 EDTMDRXAllscripts profitability poised to expand significantly, says Sterne Agee
Subscribe for More Information
07:45 EDTQCORMallinckrodt price target lowered to $77 from $90 at Leerink
Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
07:44 EDTQCORMallinckrodt remains favorite specialty pharmaceutical name, says UBS
UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use